Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug - 2Mississippi Insight for Jan. 11, 2026
- 3Higher cost, worse coverage: Affordable Care Act enrollees say expiring subsidies will hit them hard
- 4An eye for an eye: People agree about the values of body parts across cultures and eras
- 5Which camera do you believe is great for first-time clients? !
- Horses really can smell our fear, new study finds
- African Forests Have Become a Source of Carbon Emissions
- Fake new headlights rule steer Australian drivers astray
- Under pressure at home, Belgium's leader treads a tight rope with EU partners over funds for Ukraine
- Robert Irwin on winning 'Dancing With the Stars' 10 years after sister Bindi: 'This was everything I dreamed it would be and so much more'
- Tanzania president remorseful over internet shutdown on election day
- Involved Vehicles for Seniors: Track down the Best Picks for Solace and Dependability
- Surprise! Saturn's huge moon Titan may not have a buried ocean after all
- Oldest sequenced RNA reveals details about a mammoth’s final moments 40,000 years
